10x Genomics recently launched the Chromium Single Cell Controller which is a massively scalable tool for comprehensive single cell analysis. The instrument can interrogate hundreds to millions of cells, and features a simple and comprehensive workflow which enables users to quickly and easily prepare single cell sequencing libraries in less than a day.
The advantage of this partnership mainly lies in the fact that the Chromium workflows utilize and are fully compatible with the Illumina HiSeq XTM Ten, HiSeq®, NextSeq500® and MiSeq® sequencers, and enables a more expansive characterization of previously inaccessible genomic information. In addition, the Chromium Single Cell Solution allows for high-throughput, deep profiling of complex cell populations through single-cell gene expression analysis.
About 10x Genomics
10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode™ Technology within the Chromium System, researchers can now, for the first time, find new structural variants, haplotypes, and other valuable genomic information with comprehensive workflows for Single Cell, Genome and Exome applications that incorporate their pre-existing sequencing technologies.
About Alliance Global FZ LLC (AGBL)
The Alliance Global Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group's stated mission is “to improve the lives of the region's inhabitants through novel biomedical technologies and products.”
For more information, please visit: www.agbl.net
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, the expected benefits of the agreement between AGBL and 10x Genomics and other future events.
AGBL undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contacts Media: Ms. Ishah Butt
© Copyright Zawya. All Rights Reserved.